Related Experiment Video
Updated: Dec 18, 2025
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
Lower Serum miR-145 Predicts Poor Prognosis in Patients with Acute Myeloid Leukemia
Background:
The current study mainly aims to evaluate the role and clinical significance of miR-145 in the progression of AML.
Methods:
Serum and bone marrow nucleated cells (BMNc) were collected and the level of miR-145 was detected by RT-PCR. Pearson's correlation assay was carried out to analyze the correlation between serum miR-145 and clinical index. The receiver operating characteristic (ROC) curve was constructed to determine the diagnosis value of serum miR-145.
Results:
MiR-145 was significantly decreased in serum and BMNc of patients with AML compared with the control group. Pearson's correlation assay showed that serum miR-145 was positively correlated with miR-145 levels in BMNc. Further study showed that the level of serum miR-145 was much lower in AML patients with initial WBC count ≥ 50 x 109/L than that of WBC count < 50 x 109/L. Moreover, the level of serum miR-145 in prednisone poor responders was significantly lower than that in prednisone good responders. Compared with minimal residual disease (MRD) < 0.01% group, serum miR-145 was much lower in AML patients with MRD ≥ 0.01% group. Pearson's correlation analysis showed that serum miR-145 was positively correlated with MRD. In addition, miR-145 diagnosed AML with an AUC of 0.915 (95% confidence interval: 0.828 to 1.000; p < 0.001).
Conclusions:
The level of miR-145 in serum and BMNc of AML patients was significantly lower than those of the control group. Serum miR-145 was related to poor prognosis and disease recurrence of AML.
Insights
MicroRNA-145 (miR-145) is significantly decreased in acute myeloid leukemia (AML) patients. Lower serum miR-145 levels indicate a poorer prognosis and higher risk of disease recurrence in AML.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
- The specific role of miR-145 in AML requires further elucidation.
Purpose of the Study:
- To evaluate the clinical significance and diagnostic value of miR-145 in AML.
- To investigate the correlation between serum miR-145 levels and clinical indicators in AML patients.
Main Methods:
- Serum and bone marrow nucleated cells (BMNc) were collected from AML patients and healthy controls.
- Quantitative real-time PCR (RT-PCR) was used to detect miR-145 levels.
- Pearson's correlation and receiver operating characteristic (ROC) curve analyses were performed.
Main Results:
- miR-145 levels were significantly lower in serum and BMNc of AML patients compared to controls.
- Serum miR-145 levels correlated positively with BMNc miR-145 and negatively with initial white blood cell count and minimal residual disease (MRD).
- Serum miR-145 demonstrated a high diagnostic value for AML with an AUC of 0.915.
Conclusions:
- Reduced miR-145 in serum and BMNc is a hallmark of AML.
- Serum miR-145 serves as a potential biomarker for predicting poor prognosis and disease recurrence in AML.
- miR-145 holds promise as a diagnostic marker for AML.
